Engineered Nanoparticles for Drug Delivery in Cancer Therapy
The DOI matches its Crossref record; 579 of the 579 references it cites were found in a registry or an index.
Abstract
In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half‐life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real‐time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next‐generation platform for cancer therapy and many other biomedical applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Vasculature plays an essential role in the growth and metastasis of malignant tumors [103].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
Citations
Cites
Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism
Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., & Beck, J. S. (1992) · Nature · doi:10.1038/359710a0 · Cited by 16,275
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Chemistry and Properties of Nanocrystals of Different Shapes
Burda, C., Chen, X., Narayanan, R., & El-Sayed, M. A. (2005) · Chemical Reviews · doi:10.1021/cr030063a · Cited by 7,230
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Research works printed but not linked: 29
- Aruna U., 2013, Inter. J. Inn. Pharm. Res., 4, 318
- Langer R., 1998, Nature, 392, 5
- Petre C. E., 2007, Int. J. Nanomed., 2, 277
- Lao J., 2013, J. Drug Delivery, 456409
- Saif M. W., 2007, JOP, 8, 166
- Matsumura Y., 1986, Cancer Res., 46, 6387
- Xu G., 2001, Clin. Cancer Res., 7, 3314
- 10.1016/j.addr.2012.09.008 · doi:10.1016/j.addr.2012.09.008 · Paper page
- Pundir S., 2013, Int. J. Drug Res. Technol., 3, 12
- 10.1021/jp077468 · doi:10.1021/jp077468
- Mohanraj V. J., 2006, J. Pharm. Res., 5, 561
- Ma Y. D., 2011, Int. J. Nanomed., 6, 2679
- 10.1002/(SICI)1097-4636(199908)46:2<236::AID-JBM13>3.0.CO;2-F · doi:10.1002/(sici)1097-4636(199908)46:2<236::aid-jbm13>3.0.co;2-f
- Krishna R., 2000, Eur. J. Cancer Sci., 11, 265
- Kettiger H., 2013, Int. J. Nanomed., 8, 3255
- Yuan F., 1995, Cancer Res., 55, 3752
- Jain R. K., 1987, Cancer Res., 47, 3039
- 10.1021/nn900002m · DOI · Paper page
- Chidambaram M., 2012, Int. J. Pharm. Sci., 2, 117
- 10.1039/C1CS15237H · DOI · Paper page
- 10.1038/nnano.2007.223 · DOI · Paper page
- Mohanraj V. J., 2006, Trop. J. Pharm. Res., 5, 561
- Hong R. L., 1999, Clin. Cancer Res., 5, 3645
- Shamsipour F., 2009, Avicenna J. Med. Biotechnol., 1, 27
- Park J. W., 2002, Clin. Cancer Res., 8, 1172
- Uppada S. B., 2014, Int. J. Nanomed., 9, 43
- Bangham A. D., 1965, J. Mol. Biol., 13, 227
- Mueller C., 1994, Methods Cell Sci., 16, 183
- 10.1016/j.cbpa.2005.10.005 · DOI
Cited by
Items 201–300 of 1,005
Zhang, D., Teng, K., Zhao, L., Niu, L., & Yang, Q. (2023) · Advanced Materials · doi:10.1002/adma.202209789 · Cited by 148
Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy
Guimarães, P. P. G., Gaglione, S. A., Sewastianik, T., Carrasco, R. D., Langer, R., & Mitchell, M. J. (2018) · ACS Nano · doi:10.1021/acsnano.7b05876 · Cited by 140
Nanoscale Zr‐Based MOFs with Tailorable Size and Introduced Mesopore for Protein Delivery
Wang, Z., Hu, S., Yang, J., Liang, A., Li, Y., Zhuang, Q., & Gu, J. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201707356 · Cited by 137
Zhang, H., Tian, X., Shang, Y., Li, Y., & Yin, X. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b09680 · Cited by 137
Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery
Lin, D., Feng, X., Mai, B., Li, X., Wang, F., Liu, J.-X., Liu, X., Zhang, K., & Wang, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121124 · Cited by 141
Elucidating Protein Involvement in the Stabilization of the Biogenic Silver Nanoparticles
Ballottin, D., Fulaz, S. F., de Souza, M. L., Cório, P., Rodrigues, A. G., de Souza, A. O., Gaspari, P. M., Gomes, A. F., Gozzo, F. C., & Tasić, L. (2016) · Nanoscale Research Letters · doi:10.1186/s11671-016-1538-y · Cited by 146
“Countless applications have been studied in different fields, such as medicine [1, 2], material science [3], microelectronics [4], energy storing [5], and bio-”
BackgroundThe therapeutic potential of targeting ABC transporters to combat multi-drug resistance
Bugde, P., Biswas, R., Merien, F., Lu, J., Liu, D.-X., Chen, M., Zhou, S., & Li, Y. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1310841 · Cited by 135
Sohail, M. F., Rehman, M., Sarwar, H. S., Naveed, S., Qureshi, O. S., Bukhari, N. I., Hussaın, I., Webster, T. J., & Shahnaz, G. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s164518 · Cited by 140
“74 NP-based drug delivery systems have significantly improved cancer therapy and reshaped the landscape of the pharmaceutical industry.”
Recent advances in engineering iron oxide nanoparticles for effective magnetic resonance imaging
Zhao, Z., Li, M., Zeng, J., Huo, L., Liu, K., Wei, R., Ni, K., & Gao, J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.014 · Cited by 169
Emerging carrier‐free nanosystems based on molecular self‐assembly of pure drugs for cancer therapy
Zhang, X., Li, N., Zhang, S., Sun, B., Chen, Q., He, Z., Luo, C., & Sun, J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21669 · Cited by 134
Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery
Jurczyk, M., Jelonek, K., Musiał-Kulik, M., Beberok, A., Wrześniok, D., & Kasperczyk, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030326 · Cited by 133
“Gold nanoparticles are investigated as a drug delivery platform that may be decorated with different targeting agents as monoclonal antibodies, peptides, folic acid or biotin [140,141].”
BackgroundNanomedicine-mediated cancer stem cell therapy
Shen, S., Xia, J., & Wang, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.09.037 · Cited by 134
“By careful control of components, size and surface properties, nanoparticles can carry large payload of multiple drug entities and improve pharmacokinetic and pharmacodynamic profiles, while simultaneously reducing detrimental side effects to normal tissues [41].”
BackgroundUltrasmall-in-Nano Approach: Enabling the Translation of Metal Nanomaterials to Clinics
Cassano, D., Pocoví‐Martínez, S., & Voliani, V. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00664 · Cited by 137
Self-assembled mirror DNA nanostructures for tumor-specific delivery of anticancer drugs
Kim, K., Kim, H. Y., Lee, Y.-D., Ha, J. S., Kang, J. H., Jeong, H., Bang, D., Ko, Y. T., Kim, S., Lee, H., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.015 · Cited by 141
Biomolecular engineering for nanobio/bionanotechnology
Nagamune, T. (2017) · Nano Convergence · doi:10.1186/s40580-017-0103-4 · Cited by 150
Effect of ionic strength on shear-thinning nanoclay–polymer composite hydrogels
Sheikhi, A., Afewerki, S., Oklu, R., Gaharwar, A. K., & Khademhosseini, A. (2018) · Biomaterials Science · doi:10.1039/c8bm00469b · Cited by 131
DNA Nanotechnology for Precise Control over Drug Delivery and Gene Therapy
Angell, C., Xie, S., Zhang, L., & Chen, Y. (2016) · Small · doi:10.1002/smll.201502167 · Cited by 132
Nanoparticles-encapsulated polymeric microneedles for transdermal drug delivery
Chen, M., Quan, G., Sun, Y. H., Yang, D., Pan, X., & Wu, C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.039 · Cited by 137
Self-Assembled Organic Nanomaterials for Drug Delivery, Bioimaging, and Cancer Therapy
Zhang, Y., Fang, F., Li, L., & Zhang, J. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00883 · Cited by 136
Self-citationCancer-on-a-chip systems at the frontier of nanomedicine
Zhang, Y. S., Zhang, Y.-N., & Zhang, W. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.011 · Cited by 127
Self-citationTumor therapy: targeted drug delivery systems
Dai, L., Liu, J., Luo, Z. Y., Li, M., & Cai, K. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01743f · Cited by 140
Implication of Magnetic Nanoparticles in Cancer Detection, Screening and Treatment
Hosu, O., Tertiş, M., & Cristea, C. (2019) · Magnetochemistry · doi:10.3390/magnetochemistry5040055 · Cited by 136
“Reproduced with ermission from Wiley Online Library [37].”
MethodDual and multi-targeted nanoparticles for site-specific brain drug delivery
Luo, Y., Yang, H., Zhou, Y.-F., & Hu, B. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.037 · Cited by 127
Physical methods for preparation of nanomaterials, their characterization and applications: a review
Al‐Harbi, N., & El-Rahman, N. A. (2024) · Journal of Umm Al-Qura University for Applied Sciences · doi:10.1007/s43994-024-00165-7 · Cited by 166
“[81] presented two methods for subjecting the use of nanomaterials to pharmaceutical control, which are: (1) sustainable materials and their use can be controlled (2) catalytic materials, that is, materials that are sensitive to pH, light, enzymes, and temperatures.”
Chen, S., Yang, K., Tuguntaev, R. G., Mozhi, A., Zhang, J., Wang, P. C., & Liang, X.-J. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.020 · Cited by 126
Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies
Liu, L., Kshirsagar, P. G., Gautam, S. K., Gulati, M., Wafa, E. I., Christiansen, J. C., White, B. M., Mallapragada, S. K., Wannemuehler, M. J., Kumar, S., et al. (2022) · Theranostics · doi:10.7150/thno.64805 · Cited by 124
“and dose sparing and leading to enhanced antigen processing and T cell activation [236, 237].”
BackgroundNanoparticle drug delivery systems for synergistic delivery of tumor therapy
Chen, D., Liu, X., Lu, X., & Tian, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1111991 · Cited by 184
“Although it plays an important role in treatment, it is associated with multidrug resistance (MDR), toxicity, and several side effects resulting in low patient compliance (Sun et al., 2014).”
BackgroundMou, Q., Ma, Y., Zhu, X., & Yan, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.037 · Cited by 127
“Nanocarriers used for cancer therapies such 10 as liposomes [4-6], micelles [7-20], protein nanoparticles [21, 22], metallic nanoparticles [23-27], 11 inorganic nanoparticles [28, 29] can passively accumulate in the tumor site through the enhanced 12 permeability and retention (EPR) effect [30-34].”
BackgroundGold-DNA nanosunflowers for efficient gene silencing with controllable transformation
Huo, S., Gong, N., Jiang, Y. Y., Chen, F., Guo, H., Gan, Y., Wang, Z., Herrmann, A., & Liang, X. (2019) · Science Advances · doi:10.1126/sciadv.aaw6264 · Cited by 128
“Moreover, this could also be explained by the cell exocytosis effect on small-sized NPs (13).”
BackgroundNanomedicine in treatment of breast cancer – A challenge to conventional therapy
Afzal, M., Ameeduzzafar, Alharbi, K. S., Alruwaili, N. K., Al-Abassi, F. A., Al-Malki, A. A. L., Kazmi, I., Kumar, V., Kamal, M. A., Nadeem, M. S., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.016 · Cited by 123
Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma
Pei, Q., Hu, X., Liu, S., Li, Y., Xie, Z., & Jing, X. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.391 · Cited by 128
A strategy for synthesis of lipid nanoparticles using microfluidic devices with a mixer structure
Maeki, M., Saito, T., Sato, Y., Yasui, T., Kaji, N., Ishida, A., Tani, H., Baba, Y., Harashima, H., & Tokeshi, M. (2015) · RSC Advances · doi:10.1039/c5ra04690d · Cited by 123
Evans, J. C., Malhotra, M., Cryan, J. F., & O’Driscoll, C. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13576 · Cited by 136
“Targeting chemotherapies to diseased tissues overexpressing a certain receptor (such as PSMA/GCPII) allows for minimal toxicity to normal tissue, while simultaneously allowing the drug to accumulate at a much higher concentration in the tumour tissue compared with the free drug (Sun et al., 2014b; Pérez-Herrero and Fe…”
BackgroundPeng, S., Ouyang, B., Men, Y., Du, Y., Cao, Y., Xie, R., Pang, Z., Shen, S., & Yang, W. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119680 · Cited by 123
Structure of Polymer-Grafted Nanoparticle Melts
Midya, J., Rubinstein, M., Kumar, S. K., & Nikoubashman, A. (2020) · ACS Nano · doi:10.1021/acsnano.0c06134 · Cited by 123
“(3), due to the incompressibility constraint and the conservation of the total volume.”
BackgroundA Smart Nanovector for Cancer Targeted Drug Delivery Based on Graphene Quantum Dots
Iannazzo, D., Pistone, A., Celesti, C., Triolo, C., Patanè, S., Giofrè, S. V., Romeo, R., Ziccarelli, I., Mancuso, R., Gabriele, B., et al. (2019) · Nanomaterials · doi:10.3390/nano9020282 · Cited by 128
Nexus between in silico and in vivo models to enhance clinical translation of nanomedicine
Moradi Kashkooli, F., Soltani, M., Souri, M., Meaney, C., & Kohandel, M. (2021) · Nano Today · doi:10.1016/j.nantod.2020.101057 · Cited by 120
Current nanocomposite advances for biomedical and environmental application diversity
Mamidi, N., Delgadillo, R. M. V., Sustaita, A. O., Lozano, K., & Yallapu, M. M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22082 · Cited by 137
Intercalated 2D nanoclay for emerging drug delivery in cancer therapy
Zhang, Y., Long, M., Huang, P. F., Yang, H., Chang, S., Hu, Y., Tang, A., & Mao, L. (2017) · Nano Research · doi:10.1007/s12274-017-1466-x · Cited by 122
Self-citationKudarha, R. R., & Sawant, K. K. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.08.004 · Cited by 126
Zhao, H., Hu, W., Ma, H., Jiang, R., Tang, Y., Ji, Y., Lü, X., Hou, B., Deng, W., Huang, W., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201702592 · Cited by 119
Neupane, S., Patnode, K., Li, H., Baryeh, K., Liu, G., Hu, J., Chen, B., Pan, Y., & Yang, Z. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b01077 · Cited by 121
Alphandéry, E. (2019) · Nanotoxicology · doi:10.1080/17435390.2019.1572809 · Cited by 127
“On the other hand, nanoparticles smaller than 30 nm could diffuse back from the tumor to the blood vessel, and be eliminated by the MPS or kidneys (Sun et al. 2014).”
BackgroundShu, M., Tang, J., Chen, L., Zeng, Q., Li, C., Xiao, S., Jiang, Z., & Liu, J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120574 · Cited by 118
Liu, W., Ruan, M., Wang, Y., Song, R., Ji, X., Xu, J., Dai, J., & Xue, W. (2018) · Small · doi:10.1002/smll.201801754 · Cited by 118
Frtús, A., Smolková, B., Uzhytchak, M., Lunová, M., Jirsa, M., Kubinová, Š., Dejneka, A., & Lunov, O. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.036 · Cited by 122
Shahbaz, M., Akram, A., Raja, N. I., Mukhtar, T. A., Mehak, A., Fatima, N., Ajmal, M., Ali, K., Mustafa, N., & Abasi, F. (2023) · PLoS ONE · doi:10.1371/journal.pone.0274679 · Cited by 136
Zhang, R., Su, S., Hu, K., Shao, L., Deng, X., Sheng, W., & Wu, Y. F. (2015) · Nanoscale · doi:10.1039/c5nr04828a · Cited by 119
Ye, D.-X., Ma, Y.-Y., Zhao, W., Cao, H.-M., Kong, J.-L., Xiong, H.-M., & Möhwald, H. (2016) · ACS Nano · doi:10.1021/acsnano.5b07846 · Cited by 115
Cao, Z., Ma, Y., Sun, C., Lu, Z.-D., Yao, Z., Wang, J., Li, D., Yuan, Y., & Yang, X. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.7b04751 · Cited by 114
Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery
Salatin, S., Barar, J., Barzegar-Jalali, M., Adibkia, K., Milani, M. A., & Jelvehgari, M. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0782-0 · Cited by 120
“…of therapeutic agents into the nanoparticles with desirable shape, size, and surface physicochemical characteristics imposes a significant effect on improving their solubility, circulation half-life, bio-distribution and reducing the immunogenicity (Sun et al. 2014, Salatin et al. 2015a).”
BackgroundElectroporation for nanomedicine: a review
Kim, K.-S., & Lee, W. G. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00038c · Cited by 117
Mutually Synergistic Nanoparticles for Effective Thermo‐Molecularly Targeted Therapy
Luo, H., Wang, Q., Deng, Y., Yang, T., Ke, H., Yang, H., He, H., Guo, Z., Yu, D. S., Wu, H., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201702834 · Cited by 114
Polymeric nanoparticles for colon cancer therapy: overview and perspectives
You, X., Kang, Y., Hollett, G., Chen, X., Zhao, W., Gu, Z., & Wu, J. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01925k · Cited by 113
Synthesis, surface modification, and applications of magnetic iron oxide nanoparticles
Ling, W., Wang, M., Xiong, C., Xie, D., Chen, Q., Chu, X., Qiu, X., Li, Y., & Xiao, X. (2019) · Journal of materials research/Pratt's guide to venture capital sources · doi:10.1557/jmr.2019.129 · Cited by 122
Design of Smart Size‐, Surface‐, and Shape‐Switching Nanoparticles to Improve Therapeutic Efficacy
Li, X., Montague, E. C., Pollinzi, A., Lofts, A., & Hoare, T. R. (2021) · Small · doi:10.1002/smll.202104632 · Cited by 126
Solid Lipid Nanoparticles: Applications and Prospects in Cancer Treatment
Sivadasan, D., Ramakrishnan, K., Mahendran, J., Ranganathan, H., Karuppaiah, A., & Rahman, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076199 · Cited by 117
“The EPR effect influences molecular distribution through three related mechanisms: nanoparticle extravasation from blood arteries, nanoparticle diffusion into cancer tissue, and nanoparticle interaction with intracellular or extracellular targets in the tumor microenvironment [11,12].”
BackgroundXia, B., Wang, B., Shi, J., Zhang, Y., Zhang, Q., Chen, Z., & Li, J. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.01.015 · Cited by 117
Self-citationPeng, J., Dong, M., Ran, B., Li, W., Hao, Y., Yang, Q., Tan, L., Shi, K., & Qian, Z. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b01365 · Cited by 112
Arakha, M., Roy, J., Nayak, P. S., Mallick, B., & Jha, S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.05.015 · Cited by 121
“Introduction Nanoparticles with different intrinsic properties have been adopted to overcome barrier in traditional approaches, which has caused the exponential growth of nanotechnology.[1] Due to an energy band gap of 3.”
BackgroundPang, B., Zhao, Y., Luehmann, H. P., Yang, X., Detering, L., You, M., Zhang, C., Zhang, L., Li, Z., Ren, Q., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b07968 · Cited by 111
Self-citationIn Vivo Early Tumor Detection and Diagnosis by Infrared Luminescence Transient Nanothermometry
Santos, H. D. A., Ximendes, E. C., la Cruz, M. D. C. I., Chaves‐Coira, I., del Rosal, B., Jacinto, C., Monge, L., Rubia‐Rodríguez, I., Ortega, D., Mateos, S., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201803924 · Cited by 115
Nanotechnology advances towards development of targeted-treatment for obesity
Sibuyi, N. R. S., Moabelo, K. L., Meyer, M., Onani, M. O., Dube, A., & Madiehe, A. M. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0554-3 · Cited by 121
“NPs have unique properties that can be manipulated for biological applications, due to their small size and large surface area, they can be used for multimodal applications [58, 60, 62, 104].”
BackgroundNayak, P., Bentivoglio, V., Varani, M., & Signore, A. (2023) · Cancers · doi:10.3390/cancers15194846 · Cited by 135
Piri‐Moghadam, H., Ahmadi, F., Gómez‐Ríos, G. A., Boyacı, E., Reyes‐Garcés, N., Aghakhani, A., Bojko, B., & Pawliszyn, J. B. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601476 · Cited by 110
Bacterial protoplast-derived nanovesicles for tumor targeted delivery of chemotherapeutics
Kim, O. Y., Dinh, N. T. H., Park, H. T., Choi, S. J., Hong, K., & Gho, Y. S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.037 · Cited by 113
“Cancer drug delivery is no longer simple wrapping up of the drug but the largest focus lies on the targeted delivery [3,4].”
BackgroundSelf emulsifying drug delivery system for enhanced solubility and dissolution of glipizide
Agrawal, A. G., Kumar, A., & Gide, P. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.11.022 · Cited by 115
Su, L., Li, R., Khan, S. A., Clanton, R., Zhang, F., Lin, Y., Song, Y. H., Wang, H., Fan, J., Hernandez, S., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11462 · Cited by 112
Gao, D., & Lo, P. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.030 · Cited by 112
Wang, J., Du, X., Yang, J., Shen, S., Li, H., Luo, Y., Iqbal, S., Xu, C., Ye, X., Cao, J., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.022 · Cited by 114
Size-Tunable Assemblies Based on Ferrocene-Containing DNA Polymers for Spatially Uniform Penetration
Tan, J., Li, H., Hu, X., Abdullah, R., Xie, S., Zhang, L., Zhao, M., Luo, Q., Li, Y., Sun, Z., et al. (2019) · Chem · doi:10.1016/j.chempr.2019.05.024 · Cited by 111
Kimura, N., Maeki, M., Sato, Y., Ishida, A., Tani, H., Harashima, H., & Tokeshi, M. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c05489 · Cited by 109
Nano-based eye drop: Topical and noninvasive therapy for ocular diseases
Wang, C., & Pang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114721 · Cited by 114
Molecularly imprinted polymers (MIPs): emerging biomaterials for cancer theragnostic applications
Kang, M. S., Cho, E., Choi, H. E., Amri, C., Lee, J., & Kim, K. S. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00388-5 · Cited by 126
Wu, J., Deng, C., Meng, F., Zhang, J., Sun, H., & Zhong, Z. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.024 · Cited by 108
Advances in drug delivery systems based on synthetic poly(hydroxybutyrate) (co)polymers
Barouti, G., Jaffredo, C. G., & Guillaume, S. M. (2017) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2017.05.002 · Cited by 113
Motiei, M., Kashanian, S., Lucia, L. A., & Khazaei, M. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.06.010 · Cited by 110
Multifunctional inverse opal particles for drug delivery and monitoring
Zhang, B., Cheng, Y., Wang, H., Ye, B., Shang, L., Zhao, Y., & Gu, Z. (2015) · Nanoscale · doi:10.1039/c5nr02324f · Cited by 106
Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery
Xu, C., Zhang, H., Sun, C., Liu, Y., Shen, S., Yang, X., Zhu, Y., & Wang, J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.031 · Cited by 108
Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases
Prosperi, D., Colombo, M., Zanoni, I., & Granucci, F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.010 · Cited by 106
You, Y., He, L., Ma, B., & Chen, T. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703313 · Cited by 110
Nanoparticles: A Hope for the Treatment of Inflammation in CNS
Zhu, F.-D., Hu, Y.-J., Yu, L., Zhou, X.-G., Wu, J.-M., Tang, Y., Qin, D.-L., Fan, Q.-Z., & Wu, A.-G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683935 · Cited by 104
Recent Advances in Nanoparticle-Mediated Delivery of Anti-Inflammatory Phytocompounds
Conte, R., Marturano, V., Peluso, G., Calarco, A., & Cerruti, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040709 · Cited by 117
“, acidic pH in the digestive tract), and targeted and controlled delivery to achieve precise administration to a specific tissue over a determined period of time [54].”
BackgroundSharma, R. B., Liaw, K., Sharma, A., Jimenez, A. S., Chang, M., Salazar, S., Amlani, I., Kannan, S., & Kannan, R. M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.018 · Cited by 106
Nanoparticles in sonodynamic therapy: state of the art review
Xu, H., Zhang, X., Han, R., Yang, P., Ma, H., Song, Y., Lu, Z., Yin, W., Wu, X., & Wang, H. (2016) · RSC Advances · doi:10.1039/c6ra06862f · Cited by 104
Adamska, A., & Falasca, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i29.3222 · Cited by 111
Li, M., Luo, Z. Y., & Zhao, Y. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.7b03924 · Cited by 109
Cardiac Tissue Engineering on the Nanoscale
Kankala, R. K., Zhu, K., Sun, X., Liu, C., Wang, S., & Chen, A. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00913 · Cited by 107
Carrier-free nano-integrated strategy for synergetic cancer anti-angiogenic therapy and phototherapy
Wei, Z., Liang, P., Xie, J., Song, C., Tang, C., Wang, Y., Yin, X., Cai, Y., Han, W., & Dong, X. (2019) · Chemical Science · doi:10.1039/c8sc04123g · Cited by 103
Zhan, W., Alamer, M., & Xu, X. Y. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.013 · Cited by 108
The Platin-X series: activation, targeting, and delivery
Basu, U., Banik, B., Wen, R. M., Pathak, R., & Dhar, S. (2016) · Dalton Transactions · doi:10.1039/c6dt01738j · Cited by 104
Sun, Z., Zeng, Y., Zhang, H., Ma, X., Su, W., Sun, X., & Li, X. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.07.078 · Cited by 104
Pi, J., Jiang, J., Cai, H., Yang, F., Jin, H., Yang, P., Cai, J., & Chen, Z. W. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1386729 · Cited by 101
“…with specific surface modification of nanomaterials for cancer cell targeting, has emerged to provide more efficient delivery of drugs to tumors by ligand-receptor recognition and passive accumulation, which is known as the enhanced permeability and retention (EPR) effect (Sun et al., 2014b).”
BackgroundSynthesis of cellulose aerogels as promising carriers for drug delivery: a review
Liu, Z., Zhang, S., He, B., Wang, S., & Kong, F. (2021) · Cellulose · doi:10.1007/s10570-021-03734-9 · Cited by 104
“The expansion of the cellulose polymer network is positively related to the capillary action (Sun et al. 2019).”
BackgroundWang, A., Perera, Y. R., Davidson, M. B., & Fitzkee, N. C. (2016) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.6b08469 · Cited by 112
Zhang, Z., Wang, R., Huang, X., Luo, R., Xue, J., Gao, J., Liu, W., Liu, F., Feng, F., & Qu, W. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b23325 · Cited by 100
Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology
Hristova‐Panusheva, K., Xenodochidis, C., Georgieva, M., & Krasteva, N. A. (2024) · Pharmaceuticals · doi:10.3390/ph17060677 · Cited by 132
“Another illustration is the range of gold nanoparticles that, due to their optical and electrical characteristics and low toxicity [59–61], are employed as contrast agents for computed tomography [62], photoacoustic imaging [63], and photodynamic treatment [64].”
BackgroundXing, L., Shi, Q., Zheng, K., Shen, M., Ma, J., Fan, L., Liu, Y., Lin, L., Tu, W., Duan, Y., et al. (2016) · Theranostics · doi:10.7150/thno.15164 · Cited by 102
“Nanoparticles (NPs) modified with specific agents have been proven to be a promising carrier to efficiently deliver therapeutic drugs in a targeted manner to cells and tissues [7-11].”
Metal‐organic framework‐based cancer theranostic nanoplatforms
Yang, J., & Yang, Y. (2020) · Open Research (University of Surrey) · doi:10.1002/viw2.20 · Cited by 101
Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs
Sabit, H., Abdel-Hakeem, M. A., Shoala, T., Abdel-Ghany, S. E., Abdel-Latif, M. M., Almulhim, J., & mansy, M. I. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081566 · Cited by 112
“Active targeting surpasses passive targeting because it removes the need for off-site medication delivery and can reduce multi-drug tolerance [68].”
Background
Metadata
- Authors
- Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y.
- Affiliations
- Georgia Institute of Technology (US)
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2014-10-07
- Volume
- 53
- Issue
- 46
- Pages
- 12320-12364
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2134726513
- Cited by
- 2,164
- References
- 578
- Citations by year
- 2026: 57 · 2025: 146 · 2024: 163 · 2023: 153 · 2022: 209 · 2021: 200 · 2020: 221 · 2019: 237 · 2018: 257 · 2017: 230 · 2016: 180 · 2015: 109 · 2014: 2
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- engineered nanoparticles, drug delivery, cancer therapy, targeted drug delivery, enhanced permeability and retention effect, pH-responsive delivery, tumor-targeting ligands, tissue distribution, circulation half-life, immunogenicity, combination therapy, multidrug resistance, contrast media, theranostics, nanoparticle surface modification
- MeSH terms
- Animals, Antineoplastic Agents, Delayed-Action Preparations, Humans, Neoplasms, Drug Delivery Systems, Nanotechnology, Nanomedicine, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.